BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 17938272)

  • 1. O6-methylguanine-DNA-methyltransferase promoter demethylation is involved in basic fibroblast growth factor induced resistance against temozolomide in human melanoma cells.
    Fontijn D; Adema AD; Bhakat KK; Pinedo HM; Peters GJ; Boven E
    Mol Cancer Ther; 2007 Oct; 6(10):2807-15. PubMed ID: 17938272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A single cycle of treatment with temozolomide, alone or combined with O(6)-benzylguanine, induces strong chemoresistance in melanoma cell clones in vitro: role of O(6)-methylguanine-DNA methyltransferase and the mismatch repair system.
    Alvino E; Castiglia D; Caporali S; Pepponi R; Caporaso P; Lacal PM; Marra G; Fischer F; Zambruno G; Bonmassar E; Jiricny J; D'Atri S
    Int J Oncol; 2006 Oct; 29(4):785-97. PubMed ID: 16964376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of O6-benzylguanine on alkylating agent-induced toxicity and mutagenicity. In Chinese hamster ovary cells expressing wild-type and mutant O6-alkylguanine-DNA alkyltransferases.
    Cai Y; Wu MH; Xu-Welliver M; Pegg AE; Ludeman SM; Dolan ME
    Cancer Res; 2000 Oct; 60(19):5464-9. PubMed ID: 11034089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. O6-methylguanine-DNA methyltransferase, O6-benzylguanine, and resistance to clinical alkylators in pediatric primary brain tumor cell lines.
    Bobola MS; Silber JR; Ellenbogen RG; Geyer JR; Blank A; Goff RD
    Clin Cancer Res; 2005 Apr; 11(7):2747-55. PubMed ID: 15814657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy-induced O(6)-benzylguanine-resistant alkyltransferase mutations in mismatch-deficient colon cancer.
    Liu L; Schwartz S; Davis BM; Gerson SL
    Cancer Res; 2002 Jun; 62(11):3070-6. PubMed ID: 12036916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Temozolomide chemoresistance heterogeneity in melanoma with different treatment regimens: DNA damage accumulation contribution.
    Boeckmann L; Nickel AC; Kuschal C; Schaefer A; Thoms KM; Schön MP; Thomale J; Emmert S
    Melanoma Res; 2011 Jun; 21(3):206-16. PubMed ID: 21460749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea.
    Liu L; Markowitz S; Gerson SL
    Cancer Res; 1996 Dec; 56(23):5375-9. PubMed ID: 8968088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneous protection of G156A methylguanine DNA methyltransferase gene-transduced hematopoietic progenitors and sensitization of tumor cells using O6-benzylguanine and temozolomide.
    Reese JS; Davis BM; Liu L; Gerson SL
    Clin Cancer Res; 1999 Jan; 5(1):163-9. PubMed ID: 9918215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New cytotoxic agents for the treatment of metastatic malignant melanoma: temozolomide and related alkylating agents in combination with guanine analogues to abrogate drug resistance.
    Spiro T; Liu L; Gerson S
    Forum (Genova); 2000; 10(3):274-85. PubMed ID: 11007934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma.
    Maxwell JA; Johnson SP; McLendon RE; Lister DW; Horne KS; Rasheed A; Quinn JA; Ali-Osman F; Friedman AH; Modrich PL; Bigner DD; Friedman HS
    Clin Cancer Res; 2008 Aug; 14(15):4859-68. PubMed ID: 18676759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance-modifying agents. 8. Inhibition of O(6)-alkylguanine-DNA alkyltransferase by O(6)-alkenyl-, O(6)-cycloalkenyl-, and O(6)-(2-oxoalkyl)guanines and potentiation of temozolomide cytotoxicity in vitro by O(6)-(1-cyclopentenylmethyl)guanine.
    Griffin RJ; Arris CE; Bleasdale C; Boyle FT; Calvert AH; Curtin NJ; Dalby C; Kanugula S; Lembicz NK; Newell DR; Pegg AE; Golding BT
    J Med Chem; 2000 Nov; 43(22):4071-83. PubMed ID: 11063604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined effect of temozolomide and hyperthermia on human melanoma cell growth and O6-methylguanine-DNA methyltransferase activity.
    Pagani E; Falcinelli S; Pepponi R; Turriziani M; Caporaso P; Caporali S; Bonmassar E; D'Atri S
    Int J Oncol; 2007 Feb; 30(2):443-51. PubMed ID: 17203227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biochemical changes associated with a multidrug-resistant phenotype of a human glioma cell line with temozolomide-acquired resistance.
    Ma J; Murphy M; O'Dwyer PJ; Berman E; Reed K; Gallo JM
    Biochem Pharmacol; 2002 Apr; 63(7):1219-28. PubMed ID: 11960598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication.
    Aghi M; Rabkin S; Martuza RL
    J Natl Cancer Inst; 2006 Jan; 98(1):38-50. PubMed ID: 16391370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 3-aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity.
    Wedge SR; Porteous JK; Newlands ES
    Br J Cancer; 1996 Oct; 74(7):1030-6. PubMed ID: 8855970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. O(6)-methylguanine DNA-methyltransferase (MGMT) overexpression in melanoma cells induces resistance to nitrosoureas and temozolomide but sensitizes to mitomycin C.
    Passagne I; Evrard A; Depeille P; Cuq P; Cupissol D; Vian L
    Toxicol Appl Pharmacol; 2006 Mar; 211(2):97-105. PubMed ID: 16039682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-24 overcomes temozolomide resistance and enhances cell death by down-regulation of O6-methylguanine-DNA methyltransferase in human melanoma cells.
    Zheng M; Bocangel D; Ramesh R; Ekmekcioglu S; Poindexter N; Grimm EA; Chada S
    Mol Cancer Ther; 2008 Dec; 7(12):3842-51. PubMed ID: 19056673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of chemotherapy resistance in regional therapy: a novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O6-benzylguanine.
    Ueno T; Ko SH; Grubbs E; Yoshimoto Y; Augustine C; Abdel-Wahab Z; Cheng TY; Abdel-Wahab OI; Pruitt SK; Friedman HS; Tyler DS
    Mol Cancer Ther; 2006 Mar; 5(3):732-8. PubMed ID: 16546988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of single and multiple administration of an O6-benzylguanine/temozolomide combination: an evaluation in a human melanoma xenograft model.
    Wedge SR; Porteous JK; Newlands ES
    Cancer Chemother Pharmacol; 1997; 40(3):266-72. PubMed ID: 9219512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thresholds of O6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea or temozolomide.
    Kokkinakis DM; Bocangel DB; Schold SC; Moschel RC; Pegg AE
    Clin Cancer Res; 2001 Feb; 7(2):421-8. PubMed ID: 11234899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.